Largest Leukemia Center in North Carolina
We treat nearly 1,000 patients with blood cancers each year, more than any other facility in North Carolina. In addition, as a National Cancer Institute-designated Comprehensive Cancer Center, we are recognized as meeting rigorous standards for laboratory, clinical, and population-based research, and for focusing our scientific efforts on developing new and better ways to prevent, diagnose, and treat cancer. We are also part of the National Comprehensive Cancer Network (NCCN), an alliance of the nation’s leading cancer centers dedicated to improving patient care.
Team of Leukemia Specialists
Our team includes hematologic, medical, radiation and surgical oncologists, a well as dermatologists, palliative care, psychologists, infectious disease doctors, radiologists, specially trained nurses, nutritionists, and social workers. They meet regularly to discuss your condition, collect opinions, and offer advanced medical and follow-up care.
Pioneering Leukemia Treatment Options
Novel techniques, such as less intensive chemotherapy prior to a stem cell transplant, were pioneered in part at Duke, and now offer new hope to people with leukemia. We were a part of a national study that determined people with chronic myeloid leukemia (CML) taking imatinib (Gleevec) can expect to have long-term survival compared to those with traditional interferon-alpha therapy, which is now used at many medical centers across the country.
Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm
Recently, BPDCN was recognized as an uncommon subtype of acute myeloid leukemia (AML). Treatment may include the only FDA-approved agent (brand name Elzonris) or a stem cell transplant. Therapies may also be available through clinical trials.